A New Option for Patients With Migraines
October 27, 2026
Avulux is Now FDA-Authorized!
Avulux is now FDA-authorized to decrease the impact of light sensitivity in patients diagnosed with episodic migraines aged 12 years of age and older.
This is the first and only precision optical filter FDA-authorized for episodic migraine light sensitivity,1 available through Cherry Optical Lab in single vision, progressive, and plano, made to your patient’s Rx.
These lenses precisely filter out harmful blue, amber, and red light while allowing soothing green light through, delivering twice-better light quality. The FDA granted De Novo classification to Avulux as an over-the-counter Class I medical device.
Meaning, you have a new option for patients affected by light sensitivity, especially those who:
- Ask you to dim the lights, or keep sunglasses on indoors
- Point to screens, fluorescent lighting, or bright sun as what brings on or worsens an attack
- Describe glare, flicker, or harsh lighting as a daily trigger that they plan their schedule around
- Already have a migraine care plan in place, but still lose time to light
- Have tried generic tints or blue-light lenses and did not get meaningful relief
You can learn more about Avulux and how to get your hands on it by contacting your COL Sales Consultant or by clicking the button below to sign up for a webinar scheduled for November 5th at 1 PM CST.
Sign Up for the Webinar| INDICATIONS FOR USE: For patients aged 12 and older diagnosed with episodic migraine, Avulux is indicated to decrease the impact of light sensitivity. Use alongside usual care; it should not alter medication use. |
1Avulux is intended for patients diagnosed with episodic migraine, ages 12+, and used alongside usual care, including medication, not as a replacement.
